Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Human epidemiologic and genetic evidence using the Mendelian randomization approach
in large-scale studies now strongly supports that elevated lipoprotein (a)[Lp (a)] is a causal …

Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …

Background: High lipoprotein (a) is associated with increased risk of myocardial infarction
and aortic valve stenosis. Previous studies have examined the association of lipoprotein (a) …

Increased lipoprotein (a)(Lp (a)) levels are an independent predictor of coronary artery
disease (CAD), degenerative aortic stenosis (DAS), and heart failure independent of CAD …

Over the last 10 years, there have been advances on several aspects of lipoprotein (a)
which are reviewed in the present article. Since the standard immunoassays for measuring …

Abstract Purpose of Review The COVID-19 pandemic has infected over> 11 million as of
today people worldwide and is associated with significant cardiovascular manifestations …

Abstract Aims Lipoprotein (a)[Lp (a)] is a recognized causal risk factor for atherosclerotic
cardiovascular disease but its role for acute ischaemic stroke (AIS) is controversial. In this …

About one-fourth of ischemic strokes occur in working-aged individuals in the high-income
countries, with worldwide increasing incidence in this age group from 1980s to present …

Evidence from Mendelian randomization studies suggest that lipoprotein (a)(Lp (a)) has a
causal role in the development of atherosclerotic cardiovascular disease risk. However …